Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsIkki Sakuma
Assistant Professor AdjunctAbout
Copy Link
Titles
Assistant Professor Adjunct
Appointments
Endocrinology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Ikki Sakuma's published research.
Publications Timeline
A big-picture view of Ikki Sakuma's research output by year.
Gerald I Shulman, MD, PhD, MACP, MACE, FRCP
Rafael Calais Gaspar, PhD, MSc
Kitt Petersen, MD
Mario Kahn
Varman Samuel, MD, PhD
Brandon T. Hubbard
17Publications
128Citations
Publications
2026
Baxdrostat versus Osilodrostat: Steroid Biosynthesis in Human Adrenocortical Cells.
Taki Y, Kono T, Sakuma I, Hashimoto N, Yokoyama M, Kawakami E, Miki T, Sasano H, Nakamura Y, Tanaka T. Baxdrostat versus Osilodrostat: Steroid Biosynthesis in Human Adrenocortical Cells. Endocrine Connections 2026 PMID: 42307048, DOI: 10.1530/ec-25-0807.Peer-Reviewed Original ResearchConceptsCortisol-producing tumorsHuman adrenocortical cellsAdrenal cortexAdrenocortical cellsSteroid profileAldosterone-producing adenoma cellsAldosterone-producing adenomaTreatment-resistant hypertensionNormal adrenal cortexAldosterone synthase inhibitionAldosterone-mediatedAldosterone suppressionAdrenocorticotropic hormoneAdenoma cellsDose selectionSynthase inhibitionOsilodrostatCortisol suppressionExperimental ex vivo studyAldosteroneCortisol biosynthesisLC-MS/MSPrimary cellsSteroid biosynthesisAndrogen elevationCIDEB and CGI-58 differentially regulate liver lipid-droplet cholesterol to modulate metabolic dysfunction-associated steatohepatitis severity
Sakuma I, Gaspar R, Morgan H, Zheng J, Nasiri A, Dufour S, Kahn M, Guerra M, Taki Y, Kawashima Y, Yimlamai D, Perelis M, Vatner D, Petersen K, Samuel V, Tanaka T, Shulman G. CIDEB and CGI-58 differentially regulate liver lipid-droplet cholesterol to modulate metabolic dysfunction-associated steatohepatitis severity. Cell Reports 2026, 45: 117369. PMID: 42234563, DOI: 10.1016/j.celrep.2026.117369.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsCGI-58Protective effectCholesterol levelsL-amino acid-defined high-fat dietLiver-related mortalityLivers of C57BL/6J miceCGI-58 knockdownLipid dropletsCholesterol synthesis inhibitorLipid droplet proteinsCrown-like structuresHigh-fat dietBempedoic acidC57BL/6J miceLiver lipid dropletsPlasma transaminasesCidebCholine-deficientAntisense oligonucleotidesLiverCholesterolAltered cholesterolCholesterol supplementationTriglyceridesKnockdownWestern diet-induced MASH in PWK/PhJ mice identifies disruptions in amino acid and sphingolipid metabolism contributing to cardiac dysfunction
Rodríguez-López S, Pérez-Rodríguez M, Badreddine A, Gaspar R, Novaes Morgan H, Sakuma I, von Alvensleben G, Alonso-Calleja A, Everts S, Suter N, Benegiamo G, Goepfert C, de Brot S, Villalba J, Shulman G, Schoonjans K, Auwerx J. Western diet-induced MASH in PWK/PhJ mice identifies disruptions in amino acid and sphingolipid metabolism contributing to cardiac dysfunction. Nature Communications 2026 PMID: 42156763, DOI: 10.1038/s41467-026-73449-7.Peer-Reviewed Original ResearchAltmetricConceptsWestern dietCardiac dysfunctionCardiovascular diseaseMolecular profilingMetabolic changesAmino acidsCardio-metabolic disordersAssociated with cardiovascular diseaseHepatic synthesisSynthesis of ceramideCardiovascular disease riskSteatotic liver diseaseElevated cholesterol levelsExposure to WDPWK/PhJ strainAssociated with translationHepatic lipid accumulationMouse strainsMitochondrial metabolismHepatic fibrosisLiver diseaseTranscriptional profilesCholesterol levelsLiver disordersPWK/PhJLSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC
Machida T, Gong Y, Tsukioka S, Onodera A, Nakayama A, Hashimoto N, Fuchigami T, Nishimura M, Ogino T, Kurimoto R, Uematsu Y, Suzuki H, Yu H, Chen M, Yokoyama M, Sakuma I, Taki Y, Kono T, Miki T, Motohashi S, Kawashima Y, Ohara O, Yamashita S, Suzuki T, Hatanaka R, Kodama Y, Ohkubo S, Tanaka T. LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC. Nature Communications 2026, 17: 4390. PMID: 41881985, PMCID: PMC13181136, DOI: 10.1038/s41467-026-70984-1.Peer-Reviewed Original ResearchAltmetricConceptsSmall cell lung cancerCell lung cancerLimited treatment optionsLSD1 inhibitorsTumor suppressive pathwaysTumor regressionTreatment optionsLung cancerNeuroendocrine stateEpigenetic therapyTherapy candidatesLSD1 inhibitionOff-target effectsStructure-based engineeringHistone marksTranscriptional reprogrammingLSD1 activityChemoresistanceTherapyDinucleotide sitesINSM1InhibitorsMode of actionEnzymatic activityIrreversible inhibitorAxis-Specific Peripartum Management for Radiation-Induced Panhypopituitarism With Arginine Vasopressin Deficiency: A Case Report
Kono T, Miyagawa H, Kawauchi Y, Taki Y, Sakuma I, Hashimoto N, Oki Y, Shimatsu A, Tanaka T. Axis-Specific Peripartum Management for Radiation-Induced Panhypopituitarism With Arginine Vasopressin Deficiency: A Case Report. AACE Endocrinology And Diabetes 2026, 13: 512-517. PMID: 42221410, PMCID: PMC13221946, DOI: 10.1016/j.aed.2026.01.006.Peer-Reviewed Original ResearchConceptsCranial irradiationLevothyroxine dose adjustmentsSubcutaneous growth hormoneSecondary adrenal insufficiencyArginine vasopressin deficiencyIn vitro fertilizationICE chemotherapyOral desmopressinPeripartum courseCentral hypothyroidismAdrenal insufficiencyOral hydrocortisoneVasopressin deficiencyPeripartum managementThyroid replacementDose adjustmentPerinatal courseCase reportFree thyroxineGrowth hormoneReproductive medicineEndocrine profilePregnancy confirmationChemotherapyEndocrine axis
2025
Cideb knockdown in mice increases mitochondrial fat oxidation and reverses hepatic steatosis and insulin resistance by the plasma membrane sn-1,2-DAGs–PKCε–insulin receptor kinaseT1150 pathway
Zheng J, Gaspar R, Sakuma I, Hubbard B, Zhang D, Nasiri A, Kahn M, Perelis M, Samuel V, Petersen K, Shulman G. Cideb knockdown in mice increases mitochondrial fat oxidation and reverses hepatic steatosis and insulin resistance by the plasma membrane sn-1,2-DAGs–PKCε–insulin receptor kinaseT1150 pathway. Diabetologia 2025, 68: 2906-2920. PMID: 40908405, DOI: 10.1007/s00125-025-06539-8.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMitochondrial fat oxidationWhole-body energy expenditureTricarboxylic acidIn vivo rateHFD-induced hepatic steatosisHigh-fat dietHFD-induced insulin resistanceSteatotic liver diseaseAntisense oligonucleotidesHepatic lipogenesisHepatic mitochondrial oxidationHepatic insulin resistanceCidebHepatic steatosisComprehensive Lab Animal Monitoring SystemHigh-fat diet mouse modelInsulin resistanceMitochondrial oxidationMethodsC57BL/6J male miceRadio-labelled isotopesHyperinsulinaemic–euglycaemic clamp studiesKnockdownASO treatmentLipogenesisConclusions/interpretationThese findingsp53-inducible lncRNA LOC644656 causes genotoxic stress-induced stem cell maldifferentiation and cancer chemoresistance
Tamura A, Yamagata K, Kono T, Fujimoto M, Fuchigami T, Nishimura M, Yokoyama M, Nakayama A, Hashimoto N, Sakuma I, Mitsukawa N, Kawashima Y, Ohara O, Motohashi S, Kawakami E, Miki T, Onodera A, Tanaka T. p53-inducible lncRNA LOC644656 causes genotoxic stress-induced stem cell maldifferentiation and cancer chemoresistance. Nature Communications 2025, 16: 4818. PMID: 40410129, PMCID: PMC12102190, DOI: 10.1038/s41467-025-59886-w.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDNA damage responseDamage responseDNA damageDNA damage signalingResistance to genotoxic stressTGF-b signalingGenotoxic stressDamage signalingDNA-PKcsLineage-specific differentiationLoss of stemnessPoor patient survivalStem cell biologyEmbryonic stem cellsMolecular mechanismsDNACell biologyEnhanced chemoresistanceCancer chemoresistancePotential therapeutic targetDifferentiation pathwayCell propagationHuman embryonic stem cellsStem cell propagationChemoresistanceLiver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis
Sakuma I, Gaspar R, Nasiri A, Dufour S, Kahn M, Zheng J, LaMoia T, Guerra M, Taki Y, Kawashima Y, Yimlamai D, Perelis M, Vatner D, Petersen K, Huttasch M, Knebel B, Kahl S, Roden M, Samuel V, Tanaka T, Shulman G. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2502978122. PMID: 40310463, PMCID: PMC12067271, DOI: 10.1073/pnas.2502978122.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCholine-deficient l-amino acid-defined high-fat dietBempedoic acidLiver fibrosisLiver diseaseL-amino acid-defined high-fat dietAdvanced liver diseaseCholesterol contentHSD17B13 variantsHigh-fat dietTotal liver cholesterol contentTreated miceActivate signaling pathwaysVariant rs738409Liver cholesterol contentLiver lipidsFibrotic responsePromote inflammationTherapeutic approachesSteatotic liver diseaseDietary cholesterol supplementationFibrosisHuman liver samplesI148MAntisense oligonucleotidesProgressive formProtocol for characterizing craniopharyngioma subtypes and their microenvironments using single-cell RNA sequencing and immunohistochemistry
Kono T, Matsuda T, Fujimoto M, Taki Y, Sakuma I, Hashimoto N, Nakamura Y, Horiguchi K, Higuchi Y, Onodera A, Miki T, Tanaka T. Protocol for characterizing craniopharyngioma subtypes and their microenvironments using single-cell RNA sequencing and immunohistochemistry. STAR Protocols 2025, 6: 103760. PMID: 40238632, PMCID: PMC12022695, DOI: 10.1016/j.xpro.2025.103760.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsShort- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature
Taki Y, Kono T, Matsuda T, Kozu R, Fujimoto M, Sakuma I, Hashimoto N, Horiguchi K, Higuchi Y, Tanaka T. Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature. Endocrine Journal 2025, 72: 421-435. PMID: 39842795, PMCID: PMC11997266, DOI: 10.1507/endocrj.ej24-0548.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricConceptsSomatostatin receptor 5GLP-1RAsContinuous glucose monitoringGrowth hormoneOptimal first-line treatmentGLP-1 receptor agonistsEfficacy of GLP-1RAsMultireceptor somatostatin analogsEffects of pasireotideFirst-line therapyFirst-line treatmentInsulin-like growth factor-1Optimal treatment strategyControlling hormone levelsEarly detectionGrowth factor-1Pasireotide therapyInhibit insulin secretionSomatostatin analogsFirst-lineReceptor agonistsTreatment optionsPasireotideReceptor 5Treatment strategies
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Email